Navigation Links
Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
Date:7/9/2009

SOUTH SAN FRANCISCO, Calif., July 9 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced the appointment of Gary A. Lyons, to the Company's board of directors. His appointment increases the number of directors on the Poniard board to ten.

"We are pleased Gary is on the board to help guide us as we move toward our goal of commercializing picoplatin in 2010," said Jerry McMahon, Ph.D., chairman and chief executive officer of Poniard. "Gary's extensive pharmaceutical business development and commercialization experience will provide an invaluable contribution as we continue the process of identifying and securing a worldwide partner for picoplatin, and executing our strategy of building a commercial stage oncology business."

"I look forward to working with the Poniard board and management team to successfully implement its partnering and commercialization strategy for picoplatin," said Mr. Lyons. "With the pivotal Phase 3 picoplatin data in small cell lung cancer approaching, Poniard is on the cusp of a transformative time in the company's history that I look forward to being a part of."

Gary A. Lyons has served as a consultant to Poniard on matters of corporate and business development activities since April 2009, and the Company expects to expand his consulting arrangement as it moves forward with its commercialization and partnering activities. Gary has served as a Director of Neurocrine Biosciences, Inc. since February 1993 and held various executive positions with Neurocrine, including President and Chief Executive Officer, from February 1993 through January 2008. Prior to joining Neurocrine, Mr. Lyons held a number of senior management positions at Genentech, including Vice President of Business Develo
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
2. Poniard Pharmaceuticals Files Shelf Registration
3. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
4. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
5. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
6. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
7. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
8. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
9. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
10. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 EPFL and the University of  ... of John P. Donoghue . The American neuroscientist ... . The new Wyss Center for ... Geneva , has named as its director ... P. Donoghue , founder of Brown University,s Institute for ...
(Date:7/10/2014)... July 10, 2014 Product and ... very low abundance and are often “lost in ... time-consuming. , Join presenters Dr. Rowel Tobias, Senior ... John Anders, Head of Quality at Nanotherapeutics, Inc., ... that can speed detection and quantitation while achieving ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., the ... relaunch of his highly informative blog, now named Stem Cells ... are Stem Cells ?” Dr. Harman’s purpose for blogging ... basics of stem cell therapy so that pet owners can ... when considering regenerative medicine. , A veterinarian by trade, Dr. ...
(Date:7/10/2014)... PETERSBURG, Russia , July 10, 2014 ... Russian Federation Dmitry Medvedev , presented ... biopharmaceutical company BIOCAD . The Company is developing ... scope of MabNext project BIOCAD develops a number of ... cancer and autoimmune diseases. The ceremony took place at ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... Nanometre-scale gold particles are currently intensively investigated for ... carriers and molecular electronics. The particles are prepared ... reactive gold cores can be stabilised with various ... by using organothiolate ligands that have a strong ...
... Cord Blood Corporation (NYSE: CO ) ("CCBC" or ... testing, hematopoietic stem cell processing, and stem cell storage services, ... first nine months of fiscal year 2011 ended December 31, ... of Fiscal 2011 Highlights Revenue ...
... 2011 Epeius Biotechnologies ( www.epeiusbiotech.com ) announced today that ... Company,s lead anti-cancer agent, Rexin-G , the first, and ... to seek out and destroy metastatic cancer. According to Dr. ... in terms of clinical development, is that the Rexin-G product, ...
Cached Biology Technology:Fingerprints of a gold cluster revealed 2China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 2China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 3China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 4China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 5China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 6China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 7China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 8China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 9China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 10China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 11Epeius Biotechnologies' REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation From the U.S. FDA 2
(Date:7/11/2014)... Chicago is creating a new professorship in tissue ... Institute for Molecular Engineering and the Marine Biological ... the Millicent and Eugene Bell Foundation., The Eugene ... the Institute for Molecular Engineering. That endowed chair ... the MBL,s Eugene Bell Center for Regenerative Biology ...
(Date:7/11/2014)... Cell scientists have set a "mouse TRAP" to capture ... a recent study published in the Journal of ... a technique called TRAP to extract cellular and genetic ... by scientists at the Rockefeller Institute for Medical Research ... the protein-making machinery, or ribosomes, of the cell type ...
(Date:7/11/2014)... researchers from The Chinese University of Hong Kong, BGI ... soybean linked to salt tolerance, with implication for improving ... study published online in Nature Communications provides ... crop improvement. , Soybean is an important crop for ... soybeans have less genetic diversities than their wild counterparts. ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2BGI reports a novel gene for salt tolerance found in wild soybean 2
... This release is available in German . ... hibernating common pipistrelle bats under harsh conditions of snow cover. ... Max Planck Institute for Ornithology in Seewiesen and their colleagues ... birds alternative feed, they ate it and showed little or ...
... parasites from spreading throughout the body has seen Dr ... named a Young Tall Poppy by the Australian Institute ... postdoctoral fellow in the institute,s Infection and Immunity division, ... parasite,s movement. "Malaria parasites use a unique ...
... Park of Cornell University, who receives funding for basic ... (AFOSR), is investigating carbon nanostructures that may some day ... for the Air Force. "Devices that are required ... different from commercial ones in the sense that they ...
Cached Biology News:Great tits eat bats in times of need 2Malaria research wins Jake Baum a Young Tall Poppy award 2AFOSR's basic research may lead to revolutionary new devices 2
... contains a unique β-agarose digesting enzyme developed ... intact DNA and RNA from low melting ... TAE, TBE, MOPS, or phosphate buffers. The ... TAE, TBE, MOPS, and phosphate electrophoresis buffers ...
... demand is causing shortages in your laboratory ... can cause unwanted distractions, problems and delays. ... for your hard work and endeavour! Bring ... it up,and market it internationally. We work ...
... shortages in your laboratory or fellow researchers want ... problems and delays. • ... Bring us your idea and let us build ... under ISO 9001 quality assurance in design, development, ...
... (rat) - Diluted Antiserum for RIA, Host: ... U-23 (rat) Immunology Products, Host: Rabbit ... our corresponding peptide and 1 ... Neuromedin U-23 (rat) (H-9295) and ([ 1 ...
Biology Products: